Electrome Corporation Secures Rights to FDA Cleared Bioelectric Pain Therapy

Electrome Corporation today announced the successful conclusion of a multi year licensing and supply agreement with BioElectronics Corp (BIEL) covering the FDA cleared ActiPatch pulsed shortwave therapy device. The agreement establishes the device foundation of the PAINKILLER platform across clinical, retail, and direct to consumer channels in the United States.

Agreement scope

The arrangement covers priority allocation across distribution channels, co branded clinical and retail collateral, and the use of the device inside the Electrome platform's data and adherence infrastructure. The arrangement is structured to support a national rollout under the PAINKILLER brand.

About the device

ActiPatch is FDA cleared for the relief of musculoskeletal pain and edema. The device delivers pulsed shortwave therapy in a wearable form factor designed for extended daily use, and it carries a peer reviewed clinical evidence base in chronic musculoskeletal conditions.

Forward looking statements

This release includes forward looking statements regarding distribution and clinical program plans. Actual results may differ materially. Media contact information for the Electrome Communications office is available through the press center.

About the device

The bioelectric device underlying the partnership is FDA cleared for relief of musculoskeletal pain and edema, with a peer reviewed mechanism literature describing its influence on ion channel timing and inflammatory mediator release. The wearable form factor allows for extended duration of use, which is part of the modality's clinical profile in the cleared indication. The device has been used by hundreds of thousands of patients globally over the lifetime of the cleared product.

About Electrome Corporation

Electrome Corporation is the bioelectric medicine platform behind PAINKILLER and a portfolio of clinical, research, and commercial programs in the bioelectric category. The company operates the platform that connects the FDA cleared device to a coordinated patient and provider experience, with partner programs across retail, provider, affiliate, and research channels. Electrome's stated focus is on building the infrastructure layer of bioelectric medicine in a way that is rigorous, transparent, and aligned with the regulatory boundaries of the cleared device.